Originally posted by Dutchy
View Post
Klebsiella Pneumoniae Carbapenemases (KPC)
Emergence of carbapenemase resistance in Klebsiella pneumoniae and other Enterobacteriacea bacteria
Background
Multidrug resistant Gram negative organisms, including extended spectrum ß-lactamase (ESBL) producing pathogens, are an increasingly difficult problem in US hospitals. Carbapenem antibiotics, such as meropenem and imipenem, have been the cornerstone of drug treatment for serious infections caused by these pathogens. Resistance to carbapenems has been uncommon until now. Recently, Klebsiella pneumoniae has developed a novel mechanism of resistance to carbapenems, known as KPC, and has caused several extended outbreaks of infection in the Northeast region of the US.
What is a KPC?
K. pneumoniae carbapenemases (KPCs) were first described in 2001 in an isolate of Klebsiella from a hospital in North Carolina.2 KPC enzymes are encoded on gene segments that can be passed between bacteria known as plasmids. Bacteria with KPC enzymes can inactivate all penicillins, cephalosporins, aztreonam and most importantly carbapenems. KPC resistance can co-exist with other gram-negative resistance mechanisms – including ESBL, fluoroquinolone, and aminoglycoside resistances.
- snip -
The problem grows: spread of KPC resistance
KPC resistance has been reported in other states (NJ, PA, FL, GA, MD, CA, OH), including North Carolina. KPC resistance has also been reported throughout the world in Israel,4 China,5 S. America,6 and France.7 Finally, the plasmid that harbors the KPC resistance gene has transmitted to other Gram negative bacteria including Enterobacter,8 K. oxytoca,9 Pseudomonas,10 E. coli,11 and S. marcescens5.
Full article
More to read:
Klebsiella pneumoniae Carbapenemase: Extended-Spectrum beta-Lactamase Continues to Go Global
Diversity of K. pneumoniae That Produce KPC